<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112213</url>
  </required_header>
  <id_info>
    <org_study_id>ML30088</org_study_id>
    <nct_id>NCT03112213</nct_id>
  </id_info>
  <brief_title>Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment</brief_title>
  <acronym>CONIFER</acronym>
  <official_title>CONIFER (Characterization of NSAID Intake for Established Rheumatoid Arthritis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This nationwide, multicenter, single arm, prospective, non-interventional study will evaluate
      the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID
      use in a representative cohort of participant with moderate to severe active RA who have
      either responded inadequately to, or who were intolerant to previous therapy with one or more
      synthetic disease modifying anti-rheumatic drug (sDMARD), and for whom the physician has made
      the individual decision to initiate tocilizumab (subcutaneous [SC] or intravenous [IV]) as
      first biological disease modifying anti-rheumatic drug (DMARD) therapy according to the
      summary of product characteristics (SPC).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 12, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of NSAIDs Used During 14 Days Prior to First Tocilizumab Administration</measure>
    <time_frame>Day -14 to Day 0 (Baseline)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of NSAIDs Used During 14 Days After 6-8 Weeks of Tocilizumab Administration</measure>
    <time_frame>14 days after 6-8 weeks of tocilizumab administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of NSAIDs Used During 14 Days After 12-16 Weeks of Tocilizumab Administration</measure>
    <time_frame>14 days after 12-16 weeks of tocilizumab administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants by NSAIDs Dose Categories (Low-Dose and High-Dose) During 14 Days Prior to First Tocilizumab Administration</measure>
    <time_frame>Day -14 to Day 0 (Baseline)</time_frame>
    <description>NSAIDs high-dose refers to mean defined daily dose (DDD) greater than (&gt;) 100 percent (%) and low-dose refers to mean DDD lesser than or equal to (&lt;/=) 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants by NSAIDs Dose Categories (Low-Dose and High-Dose) During 14 Days After 6-8 Weeks of Tocilizumab Administration</measure>
    <time_frame>14 days after 6-8 weeks of tocilizumab administration</time_frame>
    <description>NSAIDs high-dose refers to mean DDD &gt;100% and low-dose refers to mean DDD &lt;/=100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants by NSAIDs Dose Categories (Low-Dose and High-Dose) During 14 Days After 12-16 Weeks of Tocilizumab Administration</measure>
    <time_frame>14 days after 12-16 weeks of tocilizumab administration</time_frame>
    <description>NSAIDs high-dose refers to mean DDD &gt;100% and low-dose refers to mean DDD &lt;/=100%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Take NSAIDs</measure>
    <time_frame>Day -14 up to approximately Day 126</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily Dose of NSAIDs</measure>
    <time_frame>Day -14 up to approximately Day 126</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Take NSAIDs Despite the Presence of Contraindications and Risk Factors</measure>
    <time_frame>Day -14 up to approximately Day 126</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who do not Take Gastro-Protection (Proton-Pump Inhibitors [PPIs]) While Using NSAIDs</measure>
    <time_frame>Day -14 up to approximately Day 126</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of NSAID-Prescribers</measure>
    <time_frame>Day -14 up to approximately Day 126</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of NSAID Self-Medication</measure>
    <time_frame>Day -14 up to approximately Day 126</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using NSAIDs by Disease Activity</measure>
    <time_frame>Day -14 up to approximately Day 126</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using NSAIDs by Disease Duration</measure>
    <time_frame>Day -14 up to approximately Day 126</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using NSAIDs by Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</measure>
    <time_frame>Day -14 up to approximately Day 126</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAQ-DI Score</measure>
    <time_frame>Screening (up to 28 days prior to first tocilizumab administration); Day 0 (Baseline); Weeks 6-8; Weeks 12-16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Based on 28 Joints (DAS28)</measure>
    <time_frame>Screening (up to 28 days prior to first tocilizumab administration); Day 0 (Baseline); Weeks 6-8; Weeks 12-16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease Activity Index (CDAI) Score</measure>
    <time_frame>Screening (up to 28 days prior to first tocilizumab administration); Day 0 (Baseline); Weeks 6-8; Weeks 12-16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simplified Disease Activity Index (SDAI) Score</measure>
    <time_frame>Screening (up to 28 days prior to first tocilizumab administration); Day 0 (Baseline); Weeks 6-8; Weeks 12-16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>From Baseline up to approximately Week 28</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Participants With RA</arm_group_label>
    <description>Participants with RA who are being treated with tocilizumab and NSAIDs will be observed for approximately 6 months to evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.</description>
    <arm_group_label>Participants With RA</arm_group_label>
    <other_name>RoACTEMRA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NSAIDs</intervention_name>
    <description>Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.</description>
    <arm_group_label>Participants With RA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with moderate to severe active RA who have either responded inadequately
             to, or who were intolerant to, previous therapy with one or more sDMARDs and for whom
             the physician has made the individual decision to be treated with tocilizumab (SC or
             IV)

          -  Current users of NSAIDs due to RA as assessed by the physician

        Exclusion Criteria:

          -  Contraindications to treatment with tocilizumab as per SPC

          -  Prior therapy with biological DMARDs or tofacitinib or baricitinib

          -  Prior therapy with tocilizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumazentrum Kupka</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Rheumatologie.</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik; Rheumatologie&amp;klin.Immunologie</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Mitte, Med.Klinik, Rheumatologie und Klinische Immunologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Innere Medizin - Rheumatologie</name>
      <address>
        <city>Berlin</city>
        <zip>12435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma Praxis Berlin Sven Remstedt</name>
      <address>
        <city>Berlin</city>
        <zip>12435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Silke Zinke</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Rheumatologie und klinische Immunologie an den Kreiskliniken</name>
      <address>
        <city>Burghausen</city>
        <zip>84489</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum &quot;Carl Gustav Carus&quot;; Medizinische Klinik III</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Semmler; Facharzt für Innere Medizin</name>
      <address>
        <city>Güstrow</city>
        <zip>18273</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres.Karin Babinsky und Anke Liebhaber</name>
      <address>
        <city>Halle</city>
        <zip>06128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Rheumatologie Dr. med. Hauke E. Heintz</name>
      <address>
        <city>Hamburg/Poppenbüttel</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Schwerpunktpraxis</name>
      <address>
        <city>Hannover</city>
        <zip>30161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis PD Dr.med. Bernhard Heilig</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Facharztpraxis Maren Sieburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Innere Medizin und Rheumatologie</name>
      <address>
        <city>Mansfeld</city>
        <zip>06343</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxiszentrum St. Bonifatius</name>
      <address>
        <city>Muenchen</city>
        <zip>81541</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Prof. Dr.med. Herbert Kellner</name>
      <address>
        <city>München</city>
        <zip>80935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Praxis</name>
      <address>
        <city>Neubrandenburg</city>
        <zip>17033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Neuss Dres. Irmgard Gürtler und Christoph Volberg</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr.med. Christoph Volberg</name>
      <address>
        <city>Neuss</city>
        <zip>41462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Albert</name>
      <address>
        <city>Offenburg</city>
        <zip>77652</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftsklinikum Saar GmbH, Krankenhaus Püttlingen</name>
      <address>
        <city>Püttlingen</city>
        <zip>66346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ratingen - Studienambulanz</name>
      <address>
        <city>Ratingen</city>
        <zip>40878</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr.med. Werner A. Biewer</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Schwerpunktpraxis am Feuersee</name>
      <address>
        <city>Stuttgart</city>
        <zip>70178</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Rheumatologie</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

